News >

Pegram Discusses Latest Developments in HER2+ Breast Cancer

Shannon Connelly
Published: Wednesday, Aug 09, 2017

Mark Pegram, MD

Mark Pegram, MD
Although tremendous advances have been made in HER2-positive breast cancer, Mark Pegram, MD, says researchers are just getting started.

at the meeting, Pegram, associate director for clinical research and director of the breast oncology program at Stanford Women’s Cancer Center, discussed emerging treatments in HER2-positive breast cancer and his vision for the future of the field.

OncLive:  Please provide an overview of your presentation.

Pegram: Right now, based on level 1 evidence, we have good data to support the use of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and chemotherapy in the first-line setting. That’s usually followed by T-DM1 (ado-trastuzumab emtansine; Kadcyla) in the second-line, based on the EMILIA pivotal trial, which was published in the New England Journal of Medicine just a few years ago. There was also a recent publication with the updated overall survival analysis, which remains significant.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication
x